ARDX vs. MIRM, OPK, ETNB, FLXN, XBIT, SMMT, OGN, IONS, BBIO, and CYTK
Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Mirum Pharmaceuticals (MIRM), OPKO Health (OPK), 89bio (ETNB), Flexion Therapeutics (FLXN), XBiotech (XBIT), Summit Therapeutics (SMMT), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.
Ardelyx (NASDAQ:ARDX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.
In the previous week, Ardelyx had 8 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 14 mentions for Ardelyx and 6 mentions for Mirum Pharmaceuticals. Ardelyx's average media sentiment score of 0.58 beat Mirum Pharmaceuticals' score of 0.13 indicating that Ardelyx is being referred to more favorably in the media.
Ardelyx received 410 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 72.55% of users gave Mirum Pharmaceuticals an outperform vote while only 67.49% of users gave Ardelyx an outperform vote.
Ardelyx currently has a consensus target price of $12.81, suggesting a potential upside of 98.64%. Mirum Pharmaceuticals has a consensus target price of $49.73, suggesting a potential upside of 98.35%. Given Ardelyx's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ardelyx is more favorable than Mirum Pharmaceuticals.
Ardelyx has a net margin of -41.36% compared to Mirum Pharmaceuticals' net margin of -69.67%. Ardelyx's return on equity of -41.65% beat Mirum Pharmaceuticals' return on equity.
Ardelyx has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
Ardelyx has higher earnings, but lower revenue than Mirum Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
58.9% of Ardelyx shares are held by institutional investors. 5.5% of Ardelyx shares are held by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Ardelyx beats Mirum Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Ardelyx News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
